Honey, We’ve Got a Problem

Author: Manny Gonzalez-Brito, DO, LW CMO (LifeWallet Chief Medical Officer).

The U.S. Food and Drug Administration (FDA) has taken action against four companies that have been selling honey-based products containing undisclosed prescription drug ingredients, posing potential health risks to consumers.

These four companies include: 

·      Thirstyrun LLC (also known as US Royal Honey LLC), 

·      MKS Enterprise LLC,

·      Shopaax.com, 

·      1am USA Incorporated dba Pleasure Products USA

The hidden prescription drug ingredients include Cialis (tadalafil) and Viagra (sildenafil), both FDA-approved drugs used to treat erectile dysfunction. It is crucial to emphasize that sildenafil and tadalafil are restricted drugs, and their use should only be under the supervision of a licensed healthcare professional.

These undisclosed ingredients found in the honey-based products could lead to various health risks for consumers, especially those with specific medical conditions, such as diabetes, high blood pressure, high cholesterol, or heart disease. Of particular concern is the potential interaction with nitrates present in some prescription drugs, like nitroglycerin, which may dangerously lower blood pressure. Additionally, interactions with other medications or supplements that patients are taking could increase health risks.

The FDA strongly advises consumers against unknowingly consuming honey-based products containing hidden active drug ingredients. The agency has observed an alarming increase in the illegal marketing of adulterated honey-based or honey-flavored syrup products that test positive for undisclosed drug ingredients. To safeguard consumers, the FDA is actively identifying and removing these potentially dangerous products from the market and urging stores, websites, and online marketplaces to cease their sale.

To ensure your safety, the FDA advises seeking information from your healthcare provider if you have any questions or concerns regarding these products. By doing so, consumers can make informed decisions and protect their well-being.

In conclusion, the FDA’s recent action serves as a critical reminder to remain vigilant about the products we consume and highlights the importance of transparency in labeling and adherence to prescription drug guidelines.

Disclaimer:

This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medication, medical condition or treatment.